Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Yana G. Najjar(UPMC Hillman Cancer Center), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Arivarasan Karunamurthy(University of Pittsburgh Medical Center), Rogerio I. Neves(Saint John's Health Center), Dustin McCurry(The University of Texas MD Anderson Cancer Center), Joseph J. Drabick(Penn State Milton S. Hershey Medical Center), Ghanashyam Sarikonda(Novartis (United States)), Yan Lin(Fujian Medical University), Hassane M. Zarour(University of Pittsburgh), Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), IlaSri B. Summit(Lineage Cell Therapeutics (United States)), Joseph J. Skitzki(Roswell Park Comprehensive Cancer Center), Diwakar Davar(University of Pittsburgh), Matthew P. Holtzman(UPMC Hillman Cancer Center), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Jehovana O. Bender(Navidea Biopharmaceuticals (United States)), Christian Laing(Lineage Cell Therapeutics (United States)), Yan Zang(UPMC Hillman Cancer Center), Cindy Sander(University of Pittsburgh Medical Center), Marc S. Ernstoff(National Cancer Institute), Beiru Chen(Lineage Cell Therapeutics (United States)), Ju‐Young Kim(Lineage Cell Therapeutics (United States)), Lin Huang(University of Maryland, College Park), Anil Pahuja(Lineage Cell Therapeutics (United States)), Zeni Alfonso(Lineage Cell Therapeutics (United States)), Jennifer Tsau(Lineage Cell Therapeutics (United States)), James F. Pingpank(University of Pittsburgh Medical Center), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Amy Rose(University of Pittsburgh Medical Center), John M. Kirkwood(UPMC Hillman Cancer Center)
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k